Shu-Zhen Chen received her MD and PhD from Peking Union Medical College. Currently, she is working as a professor in Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences. She focuses on tumor-related cell apoptosis, cell signaling pathways, protein-protein interactions, and biotechnology drug research. The major contents include the following 5 aspects: (1) Biomarkers and drugs target research; (2) The role of tumor microenvironment in tumor invasion and metastasis; (3) Research and development of anti-cancer drugs including anti-tumor antibiotics and anti-tumor biotechnology drugs (antibodies and protein drugs); (4) Regulation of death receptors by small therapeutic molecules, especially the expression of TRAIL receptors and their significance in drug-induced apoptosis and cancer treatment; (5) Regulation of the chemosensitivity of tumor cells to anticancer drugs through biochemical regulators. Until now, she has presided over a number of national-level projects and published more than 70 papers (including chapters in books), among which there are more than 50 articles published as the first author and corresponding author. Furthermore, she has applied for 6 invention patents, among which 4 patents have been obtained, and 2 are in the substantive examination stage.